1746P Impact of PD-1/PD-L1 blockade therapy in COVID-19 infected cancer patients (pts) hospitalization: Results of an Italian study in the province of Modena and Reggio Emilia during SARS-CoV-2 outbreak

Background: Higher incidence of severe events in cancer pts affected by COVID-19 have been reported However, the association with oncological treatments is not clear yet Recommendations have been released by Italian scientific society and colleges (AIOM, CIPOMO, COMU) according to the risk of infection and tumor characteristics, suggesting telephone consultations and, if suitable, treatments delay Methods: In Modena and Reggio Emilia Cancer Centers, previous Ethical Committee approval, medical reports of pts undertaking immunotherapy between January 1st - April 30th 2020 were collected According to WHO indications COVID-19 infection was identified by thoracic CT scan and RT-PCR of nasopharyngeal specimens For those pts we estimated the risk of infection and complications that lead to hospitalization Results: A total of 337 pts with solid tumors treated with anti-PD1/PDL-1 antibody regardless the line of treatment was identified Cancer diagnosis included 156 (46,3%) lung, 74 (22%) melanoma, 36 (10,7%) kidney, 23 (7%) colorectal, 12 (3,4%) head and neck, 36 (10,6%) miscellaneous Only 3 pts (0 9%), with advanced disease and in first line therapy were hospitalized for COVID-19 (Table) The onset symptom was fever in 2 pts, and subjective dyspnea in 1 pt Subsequently, they develop respiratory distress and underwent to non-invasive assisted ventilation, receiving hydroxychloroquine, steroids, low molecular weight heparin Tocilizumab was administered in 1 pt due to progressive increase of serum IL-6 values Nobody was admitted in Intensive Care Unit Since the last update, May 15th 2020, 1 pt died;the others have recovered with negative nasopharyngeal swab [Formula presented] Conclusions: Although not conclusive, in our series, cancer pts infected by COVID-19 receiving immunotherapy do not appear to be exposed to greater risk of recovery Legal entity responsible for the study: Angela Damato Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest